istock-895258514-natasaadzic
natasaadzic / iStockphoto.com
4 September 2018Big Pharma

EMA cuts MHRA out of drug reviews ahead of Brexit

The European Medicines Agency (EMA) has reportedly put a stop to the UK’s role in evaluating new EU medicines for sale as Brexit looms.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
12 November 2018   Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
4 October 2018   The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.
Big Pharma
24 August 2018   The UK will fall outside of the European Medicines Agency in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency to take on the functions currently undertaken by the EU for medicines on the UK market.